Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Interferon-β-1b: a review of its use in multiple sclerosis.
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.
Nephrotic-range proteinuria on interferon-β treatment: immune-induced glomerulonephritis or other pathway?
Progressive Multifocal Leukoencephalopathy: Why Gray and White Matter.
Boxed warning of HBV risk added to Rituxan, Arezerra
Repurposing drugs for disease modification in multiple sclerosis
Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.
Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians.
Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci.
CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells.
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.
A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
Molecular characterization of a peripheral receptor for cannabinoids.
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
Glatiramer acetate (GA) prevents TNF-α-induced monocyte adhesion to primary endothelial cells through interfering with the NF-κB pathway.
Effect of IFN β-1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients.
Gray matter SWI-filtered phase and atrophy are linked to disability in MS .
Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients
Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO)
Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis.
Adaptive myelination from fish to man.
Teriflunomide for multiple sclerosis.
Pharmacodynamics of Dimethyl Fumarate are Tissue-specific and Involve NRF2-dependent and -independent Mechanisms.

Pages